The Technical Analyst
Prometheus Biosciences, [RXDX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Prometheus Biosciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.09% $199.92
America/New_York / 15 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9 558.52 mill |
| EPS: | -3.54 |
| P/E: | -56.47 |
| Earnings Date: | May 13, 2021 |
| SharesOutstanding: | 47.81 mill |
| Avg Daily Volume: | 1.218 mill |
| RATING 2023-06-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -56.47 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -9.61x |
| Company: PE -56.47 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 197.52 - 202.32 ( +/- 1.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-16 | Hendrix Martin | Sell | 2 071 | Common Stock |
| 2023-06-16 | Hendrix Martin | Sell | 40 000 | Stock Option (right to buy) |
| 2023-06-16 | Hendrix Martin | Sell | 20 500 | Stock Option (right to buy) |
| 2023-06-16 | Laur James | Sell | 2 071 | Common Stock |
| 2023-06-16 | Laur James | Sell | 40 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -86.75 |
| Last 100 transactions |
| Buy: 394 552 | Sell: 5 154 734 |
Forecast:
01:40 - $208.45
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $199.92 (0.09% ) |
| Volume | 1.787 mill |
| Avg. Vol. | 1.218 mill |
| % of Avg. Vol | 146.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RXDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RXDX
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Latest Press Releases
2023-05-22 14:40:00 - Press Release
Prometheus Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Prometheus Biosciences, Inc. - Rxdx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of prometheus biosciences, inc. (nasdaqgs: rxdx) to merck & co., inc. (nyse: mrk). under the terms of the proposed transaction, shareholders of prometheus will receive $200.00 in cash for each share of prometheus that they own. ksf is seeking to determine whether this consideration and the process that led to.
2023-04-21 13:40:00 - Press Release
Prometheus Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Prometheus Biosciences, Inc. - Rxdx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of prometheus biosciences, inc. (nasdaqgs: rxdx) to merck & co., inc. (nyse: mrk). under the terms of the proposed transaction, shareholders of prometheus will receive $200.00 in cash for each share of prometheus that they own.
2023-04-16 06:00:00 - Press Release
Merck Strengthens Immunology Pipeline With Acquisition Of Prometheus Biosciences, Inc.
Rahway, n.j. & san diego--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside the united states and canada, and prometheus biosciences, inc. (“prometheus”) (nasdaq: rxdx) today announced that the companies have entered into a definitive agreement under which merck, through a subsidiary, has agreed to acquire prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
2023-03-09 08:30:00 - Press Release
Prometheus Biosciences To Present At The Oppenheimer 33rd Annual Healthcare Conference
San diego, march 09, 2023 (globe newswire) -- prometheus biosciences, inc. (nasdaq: rxdx), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the oppenheimer 33rd annual healthcare conference on march 13, 2023 at 10:40 am et.
2023-02-09 16:00:00 - Press Release
Prometheus Biosciences To Present At The Svb Securities Global Biopharma Conference
San diego, feb. 09, 2023 (globe newswire) -- prometheus biosciences, inc. (nasdaq: rxdx), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the svb securities global biopharma conference on february 14, 2023 at 12:00 pm et.
Latest News
2023-08-01 06:32:40 - CNBC
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
2023-05-12 13:42:27 - Zacks Investment Research
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-05-09 19:07:22 - Zacks Investment Research
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
Prometheus Biosciences, Inc. (RXDX) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.82 per share a year ago.
2023-04-20 16:24:00 - The Motley Fool
Why Prometheus Biosciences Stock Is Skyrocketing This Week
Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merck's pipeline.
2023-04-19 13:13:13 - Pulse2
Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to buy Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion.
2023-04-18 04:36:03 - Zacks Investment Research
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-04-17 17:55:46 - CNBC Television
Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus
Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.
2023-04-17 12:23:06 - Proactive Investors
Roivant Sciences shares spike on Merck-Prometheus Biosciences deal
Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to bring to market their promising bowel disease drug candidate. The acquisition adds Prometheus' monoclonal antibody treatment PRA023 being developed for ulcerative colitis (UC), Crohn's disease, and systematic sclerosis-associated interstitial lung disease to Merck's drug pipeline.
2023-04-17 12:09:48 - Seeking Alpha
Merck's Prometheus Acquisition Is A Step In The Right Direction
Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive portfolio of assets, but its pipeline is sparse and its valuation is higher.
2023-04-17 12:09:30 - The Motley Fool
Why Shares of Prometheus Biosciences Are Soaring Monday
Prometheus' lead therapy treats ulcerative colitis and a variety of autoimmune disorders. Merck is looking to supplement its immunology portfolio.